As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

Systemic Lupus Erythematosus is one of the most complex autoimmune diseases seen in modern medicine, affecting multiple organs and presenting differently from one patient to another. Often referred to ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral ...

The Commonwealth Transportation Board at its Jan. 6 meeting in Richmond awarded a $218.9 million contract to Triton ...

China: CAR T-cell therapy, already in use for certain B-cell–driven autoimmune diseases such as lupus, has now demonstrated ...